Clinical trial · Observational
Determining Patterns In Study Experiences of Neuroblastoma Patients
Neuroblastoma Clinical Trials: Looking at Patterns About How Patients Feel About Participating in Clinical Trials
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Historically, participation in clinical research is highly skewed towards particular demographic groups of people. This study will invite several participants to gather a wide range of information on clinical trial experiences for neuroblastoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of neuroblastoma. The data collected from this study will help improve future outcomes for all neuroblastoma patients as well as those in under-represented demographic groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Number of patients who decide to enroll in a neuroblastoma clinical trial
- timeFrame
- 3 months
- measure
- Rate of patients who remain in neuroblastoma clinical trial to trial completion
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of neuroblastoma * Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. Exclusion Criteria: * Women of childbearing potential without a negative pregnancy test; or women who are lactating. * Any serious and/or unstable pre-existing medical disorders * Enrolled in another research study
References
Publications (3)
- BACKGROUNDPark JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 Aug 27;322(8):746-755. doi: 10.1001/jama.2019.11642. PMID 31454045
- BACKGROUNDPark JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer. 2022 Nov 1;128(21):3775-3783. doi: 10.1002/cncr.34445. Epub 2022 Sep 13. PMID 36101004
- BACKGROUNDKhomenko VI, Stoliarchuk NP, Ilyk OP. [Reserves of quality]. Veterinariia. 1979 Mar;(3):14-6. No abstract available. Russian. PMID 442501